UY31433A1 - Nuevos anticuerpos especificos de los peptidos - amiloides y sus usos como agentes de diagnostico o drogas - Google Patents
Nuevos anticuerpos especificos de los peptidos - amiloides y sus usos como agentes de diagnostico o drogasInfo
- Publication number
- UY31433A1 UY31433A1 UY31433A UY31433A UY31433A1 UY 31433 A1 UY31433 A1 UY 31433A1 UY 31433 A UY31433 A UY 31433A UY 31433 A UY31433 A UY 31433A UY 31433 A1 UY31433 A1 UY 31433A1
- Authority
- UY
- Uruguay
- Prior art keywords
- peptides
- amiloids
- diagnosis
- drugs
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion se refiere a un anticuerpo monoclonal que se une específicamente a la region N-terminal de péptidos AB(Beta)8-x, estando x comprendido desde 11 a 42, y que no reconoce ni AB(Beta)1-40 ni AB(Beta)1-42 y que presenta una elevada afinidad con respecto a péptidos AB(Beta)8-x, tal como se determina mediante la formacion de complejo inmunologico entre el anticuerpo monoclonal y el péptido AB(Beta)8-x.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07119537 | 2007-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31433A1 true UY31433A1 (es) | 2009-05-29 |
Family
ID=38925731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31433A UY31433A1 (es) | 2007-10-29 | 2008-10-24 | Nuevos anticuerpos especificos de los peptidos - amiloides y sus usos como agentes de diagnostico o drogas |
Country Status (27)
Country | Link |
---|---|
US (1) | US8343493B2 (es) |
EP (1) | EP2205633A1 (es) |
JP (1) | JP5421277B2 (es) |
KR (1) | KR20100097651A (es) |
CN (1) | CN101883792B (es) |
AP (1) | AP2957A (es) |
AR (1) | AR069085A1 (es) |
AU (1) | AU2008317705B2 (es) |
CA (1) | CA2703825A1 (es) |
CL (1) | CL2008003197A1 (es) |
CO (1) | CO6270369A2 (es) |
CR (1) | CR11396A (es) |
EA (1) | EA201070539A1 (es) |
EC (1) | ECSP10010142A (es) |
HN (1) | HN2010000880A (es) |
IL (1) | IL205398A0 (es) |
MA (1) | MA31793B1 (es) |
MX (1) | MX2010004660A (es) |
MY (1) | MY155144A (es) |
NI (1) | NI201000075A (es) |
NZ (1) | NZ585000A (es) |
TN (1) | TN2010000197A1 (es) |
TW (1) | TW200936605A (es) |
UA (1) | UA103602C2 (es) |
UY (1) | UY31433A1 (es) |
WO (1) | WO2009056490A1 (es) |
ZA (1) | ZA201002989B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA029481B1 (ru) * | 2007-01-05 | 2018-04-30 | Юнивэсэти Оф Цюрих | Способ получения человеческого рекомбинантного антитела, специфично связывающего вариант эндогенного белка, формирующий аномальные патологические белковые структуры путем агрегации, олигомеризации или образования фибрилл |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
EP2949666B1 (en) | 2008-12-19 | 2018-12-19 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
PE20130527A1 (es) | 2010-03-03 | 2013-05-09 | Boehringer Ingelheim Int | Polipeptidos de union a a-beta biparatopicos |
EP2511296A1 (en) * | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
AU2012272790B2 (en) | 2011-06-23 | 2016-10-06 | Biogen International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
EP2847217B1 (en) | 2012-05-10 | 2017-10-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
KR20180085736A (ko) * | 2015-11-09 | 2018-07-27 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체 |
EP3487523B1 (en) | 2016-07-19 | 2023-09-06 | Duke University | Therapeutic applications of cpf1-based genome editing |
FI3672631T3 (fi) | 2017-08-22 | 2023-06-29 | Biogen Ma Inc | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
WO2023111168A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | A novel antibody for detection of amyloid beta 42 (aβ42) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1523499A2 (en) * | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
-
2008
- 2008-10-24 CN CN200880119109.XA patent/CN101883792B/zh not_active Expired - Fee Related
- 2008-10-24 US US12/740,217 patent/US8343493B2/en not_active Expired - Fee Related
- 2008-10-24 AP AP2010005249A patent/AP2957A/xx active
- 2008-10-24 AU AU2008317705A patent/AU2008317705B2/en not_active Ceased
- 2008-10-24 EP EP08844119A patent/EP2205633A1/en not_active Withdrawn
- 2008-10-24 UY UY31433A patent/UY31433A1/es unknown
- 2008-10-24 KR KR1020107009533A patent/KR20100097651A/ko not_active Application Discontinuation
- 2008-10-24 MY MYPI2010001941A patent/MY155144A/en unknown
- 2008-10-24 MX MX2010004660A patent/MX2010004660A/es active IP Right Grant
- 2008-10-24 CA CA2703825A patent/CA2703825A1/en not_active Abandoned
- 2008-10-24 EA EA201070539A patent/EA201070539A1/ru unknown
- 2008-10-24 WO PCT/EP2008/064432 patent/WO2009056490A1/en active Application Filing
- 2008-10-24 NZ NZ585000A patent/NZ585000A/xx not_active IP Right Cessation
- 2008-10-24 UA UAA201006547A patent/UA103602C2/ru unknown
- 2008-10-24 JP JP2010531496A patent/JP5421277B2/ja not_active Expired - Fee Related
- 2008-10-27 TW TW097141147A patent/TW200936605A/zh unknown
- 2008-10-28 CL CL2008003197A patent/CL2008003197A1/es unknown
- 2008-10-28 AR ARP080104708A patent/AR069085A1/es unknown
-
2010
- 2010-04-28 CR CR11396A patent/CR11396A/es unknown
- 2010-04-28 HN HN2010000880A patent/HN2010000880A/es unknown
- 2010-04-28 IL IL205398A patent/IL205398A0/en unknown
- 2010-04-29 TN TN2010000197A patent/TN2010000197A1/fr unknown
- 2010-04-29 CO CO10050927A patent/CO6270369A2/es active IP Right Grant
- 2010-04-29 NI NI201000075A patent/NI201000075A/es unknown
- 2010-04-29 ZA ZA2010/02989A patent/ZA201002989B/en unknown
- 2010-04-29 EC EC2010010142A patent/ECSP10010142A/es unknown
- 2010-04-29 MA MA32798A patent/MA31793B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
HN2010000880A (es) | 2014-03-10 |
CO6270369A2 (es) | 2011-04-20 |
AP2957A (en) | 2014-08-31 |
TN2010000197A1 (en) | 2011-11-11 |
AU2008317705A1 (en) | 2009-05-07 |
TW200936605A (en) | 2009-09-01 |
MX2010004660A (es) | 2010-07-30 |
JP2011502139A (ja) | 2011-01-20 |
CA2703825A1 (en) | 2009-05-07 |
WO2009056490A1 (en) | 2009-05-07 |
EP2205633A1 (en) | 2010-07-14 |
US20110059092A1 (en) | 2011-03-10 |
CL2008003197A1 (es) | 2010-01-15 |
ECSP10010142A (es) | 2010-07-30 |
MY155144A (en) | 2015-09-15 |
AU2008317705B2 (en) | 2014-06-05 |
UA103602C2 (ru) | 2013-11-11 |
JP5421277B2 (ja) | 2014-02-19 |
NI201000075A (es) | 2010-09-23 |
AR069085A1 (es) | 2009-12-30 |
IL205398A0 (en) | 2010-12-30 |
KR20100097651A (ko) | 2010-09-03 |
US8343493B2 (en) | 2013-01-01 |
CN101883792B (zh) | 2014-08-27 |
CR11396A (es) | 2012-10-18 |
CN101883792A (zh) | 2010-11-10 |
MA31793B1 (fr) | 2010-10-01 |
EA201070539A1 (ru) | 2010-10-29 |
ZA201002989B (en) | 2011-07-27 |
NZ585000A (en) | 2012-08-31 |
AP2010005249A0 (en) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31433A1 (es) | Nuevos anticuerpos especificos de los peptidos - amiloides y sus usos como agentes de diagnostico o drogas | |
MA46299B1 (fr) | Molécule de polypeptide à double spécificité améliorée | |
CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
CR20120127A (es) | Anticuerpos monoclonales | |
PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
RS53291B (en) | BETA 1-42 SPECIFIC MONOCLONIC ANTIBODIES WITH THERAPEUTIC PROPERTIES | |
AR063090A1 (es) | Proteinas de union al antigeno del receptor de la il-17 | |
CR11374A (es) | Proteinas humanas de union a antigenos del gm-csf | |
EP2535351A3 (en) | Dual specificity antibody fusions | |
SG10201807877TA (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
GT200900043A (es) | Anticuerpos monoclonales humanos especificos para light humano antagonistas | |
ECSP14013307A (es) | Genzyme corporation | |
AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
TR201901841T4 (tr) | Her antikorlarının sabit dozlaması. | |
ATE552276T1 (de) | Modifizierter anti-cd52-antikörper | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
CR20110559A (es) | Anticuerpos específicos para cadherina-17 | |
PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
TR201819828T4 (tr) | Anti-fosfolipaz d4 antikoru. | |
MA46988A1 (fr) | Formulation liquide d'anticorps anti-tnf alpha | |
MX343873B (es) | Ensayo de diagnostico de anticuerpo. | |
GB0611708D0 (en) | Novel antibodies against prion protein and uses thereof | |
UA98100C2 (ru) | Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его | |
ATE456051T1 (de) | Testsystem zum nachweis von salmonellen |